WO2001028472A1 - Drug delivery device - Google Patents
Drug delivery device Download PDFInfo
- Publication number
- WO2001028472A1 WO2001028472A1 PCT/US2000/024983 US0024983W WO0128472A1 WO 2001028472 A1 WO2001028472 A1 WO 2001028472A1 US 0024983 W US0024983 W US 0024983W WO 0128472 A1 WO0128472 A1 WO 0128472A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug delivery
- pharmaceutically active
- active agent
- delivery device
- inner core
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00885—Methods or devices for eye surgery using laser for treating a particular disease
- A61F2009/00891—Glaucoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Definitions
- the present invention generally pertains to biocompatible implants for localized delivery of pharmaceutically active agents to body tissue. More particularly, but not by way of limitation, the present invention pertains to biocompatible implants for localized delivery of pharmaceutically active agents to the posterior segment of the eye.
- Age related macular degeneration AMD
- CNV choroidal neovascularization
- retinopathies i.e. diabetic retinopathy, vitreoretinopathy
- retinitis i.e. cytomegalovirus (CMV) retinitis
- uveitis macular edema
- glaucoma a grouping of retinopathies.
- Age related macular degeneration is the leading cause of blindness in the elderly. ARMD attacks the center of vision and blurs it, making reading, driving, and
- wet ARMD is the type of ARMD that most often causes blindness. In wet ARMD, newly formed choroidal blood vessels (choroidal neovascularization (CNV)) leak fluid and cause progressive CNV neovascularization (CNV)
- U.S. Patent No. 5,824,072 to Wong discloses a non-biodegradable polymeric implant with a pharmaceutically active agent disposed therein.
- the pharmaceutically active agent diffuses through the polymer
- the pharmaceutically active agent may include drugs for the treatment of macular degeneration and diabetic retinopathy.
- the implant is placed substantially within the tear fluid upon the outer surface of the eye over an avascular region, and may be anchored in the conjunctiva or sclera; episclerally or
- intrasclerally over an avascular region substantially within the suprachoroidial space over an avascular region such as the pars plana or a surgically induced avascular region; or in
- the implant may be used to deliver neovascular inhibitors for the treatment of ARMD and drugs for the treatment of retinopathies, retinitis, and CMV retinitis.
- the pharmaceutically active agent diffuses through the polymer body of the implant.
- U.S. Patent No. 5,773,019 to Ashton et al. discloses a non-bioerodable polymer implant for delivery of certain drugs including angiostatic steroids and drugs such as
- cyclosporine for the treatment of uveitis.
- the pharmaceutically active agent diffuses through the polymer body of the implant.
- Drug release from these devices depends on the porosity and diffusion characteristics of the matrix or membrane, respectively. These parameters must be tailored for each drug moiety to be used with these devices. Consequently, these requirements generally increase the complexity and cost of such implants.
- U.S. Patent No. 5,824,073 to Peyman discloses an indentor for positioning in the eye.
- the indentor has a raised portion that is used to indent or apply pressure to the sclera over the macular area of the eye. This patent discloses that such pressure decreases
- such a device should be easy and
- such an implant should be capable of use in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject.
- such an implantable drug delivery device is especially needed for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat
- ARMD CNV
- retinopathies retinitis, uveitis, macular edema, and glaucoma.
- One aspect of the present invention comprises a drug delivery device including a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface.
- An inner core comprising a pharmaceutically active agent is disposed in the well.
- the present invention comprises a method of delivering a pharmaceutically active agent to a target tissue within a body.
- a drug delivery device is provided.
- the drug delivery device includes a body having an internal surface and a well having an opening to the internal surface, and an inner core disposed in the well
- the device comprising a pharmaceutically active agent.
- the device is disposed within the body so that the pharmaceutically active agent is in communication with the target tissue through
- the present invention comprises an ophthalmic drug delivery
- An inner core comprising a
- the present invention comprises a method of delivering a
- a drug delivery device is
- the drug delivery device includes a body having a scleral surface and a well having an opening to the scleral surface, and an inner core disposed in the well comprising a pharmaceutically active agent.
- the device is disposed within the eye so that the pharmaceutically active agent is in communication with the sclera through the opening.
- the present invention comprises a method of delivering a pharmaceutically active agent to an eye having a sclera, a Tenon's capsule, and a macula.
- a drug delivery device comprising a body having a pharmaceutically active agent
- the device is disposed on an outer surface of the sclera. Below the Tenon's capsule, and proximate the macula.
- FIG. 1 is a side sectional view of a drug delivery device according to a preferred embodiment
- FIG. 2 is a side sectional view of a second drug delivery device according to a
- FIG. 3 is a side sectional view schematically illustrating the human eye
- FIG. 4 is detailed cross-sectional view of the eye of FIG. 3 along line 4-4;
- FIG. 5 is a perspective view of an ophthalmic drug delivery device according to a
- FIG. 6 A is a side sectional view of the ophthalmic drug delivery device of FIG. 5;
- FIG 6B is an enlarged cross-sectional view of the ophthalmic drug delivery device
- FIG. 6 A taken along line 6B-6B; and
- FIG. 7 is a graphical illustration of the results of a pharmacokinetic study with New Zealand White rabbits implanted with the ophthalmic drug delivery device of FIGS. 5 through 6B showing the mean concentration of a pharmaceutically active agent at a target site in the retina and choroid of the rabbits as a function of time.
- FIGS. 1 through 7 of the drawings like numerals being used for like and corresponding parts of the various drawings.
- FIG. 1 schematically illustrates a drug delivery device 10 according to a preferred
- Device 10 may be used in any case where localized delivery of a pharmaceutically active agent to body tissue is required.
- device 10 may be used to treat a medical disorder of the eye, ear, nose, throat,
- Device 10 may be used in humans or animals.
- Device 10 generally includes a body 12 having an internal surface 14 and an
- body 12 preferably has a generally rectangular three-dimensional geometry with a proximal end 18 and a distal end 20. Body 12 may
- body 12 may have any other geometry that has an internal surface 14 for placement proximate a target tissue in the body of a patient.
- body 12 may have a cylindrical, an oval, a square, or other polygonal three-dimensional geometry.
- Body 12 includes a well or cavity 22 having an opening 24 to internal surface 14.
- Inner core 26 is preferably disposed in well 22.
- Inner core 26 is preferably a tablet
- inner core 26 may
- a retaining member 28 is preferably disposed proximate opening 24.
- Retaining member 28 prevents inner core 26 from falling out of well 22.
- retaining member 28 is preferably a continuous rim or lip disposed circumferentially around opening 24 having a diameter slightly less than the diameter of tablet 26.
- retaining member 26 may comprise one or more members that extend from body 12 into opening 24.
- inner core 26 may alternatively comprise a suspension, solution, powder, or combination
- internal surface 14 is formed without opening 24, and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion of internal surface 14 below inner core 26.
- device 10 may be formed without well 22 or inner core 26, and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughout body
- the pharmaceutically active agent diffuses through body 12 into the target tissue.
- the geometry of device 10 maximizes communication between the
- Internal surface 14 preferably physically contacts the target tissue.
- the target tissue has a generally flat surface, device 10 would be appropriate
- a device 10a shown in FIG. 2 having a generally concave internal surface 14a designed to mate with such a target surface may be utilized.
- Corners 30 of proximal end 18a, and corners 32 of distal end 20a, may be slanted and/or
- Retaining member 28 is preferably designed with a minimum thickness necessary
- inner core 26 may be formed so that surface 26a physically contacts the target tissue.
- device 10 or 10a may be disposed in the body of a patient so that internal surface 14 or 14a is disposed proximate the target tissue.
- internal surface 14 or 14a physically contacts intermediate tissue disposed between it and the target tissue.
- the pharmaceutically active agent of inner core 26 communicates with the target tissue through opening 24 and this intermediate tissue.
- body 12 preferably comprises a biocompatible, non- bioerodable material.
- Body 12 more preferably comprises a biocompatible. non- bioerodable polymeric composition.
- Said polymeric composition may be a homopolymer, a copolymer, straight, branched, cross-linked, or a blend. Examples of polymers suitable
- polymeric composition for use in said polymeric composition include silicone, polyvinyl alcohol, ethylene vinyl acetate, polylactic acid, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, polyglycolic acid, polylactic-glycolic acid, cellulose esters, polyethersulfone, acrylics,
- Said polymeric composition most preferably comprises silicone.
- said polymeric composition may also comprise other conventional materials that affect its physical properties, including, but not limited to, porosity, tortuosity, permeability, rigidity, hardness, and smoothness. Exemplary materials affecting certain ones of these
- polymeric composition may comprise other conventional materials that affect its chemical properties, including, but not limited to, toxicity, hydrophobicity, and body 12 - inner
- Body 12 is preferably impermeable to the pharmaceutically active
- body 12 When body 12 is made from a generally elastic polymeric composition, the diameter of well 22 may be slightly less than the diameter of inner core 26. This frictional fit secures inner core 26 within well 22. In this embodiment, body 12 may be formed without retaining member 28. if desired.
- Inner core 26 may comprise any pharmaceutically active agents suitable for localized delivery to a target tissue.
- pharmaceutically active agents suitable for inner core 26 are anti-infectives, including, without limitation, antibiotics, antiviral s. and antifungals; antiallergenic agents and mast cell stabilizers; steroidal and non-steroidal anti-inflammatory agents; combinations of anti-infective and anti-inflammatory agents; decongestants; anti-glaucoma agents, including, without limitation, adrenergics, ⁇ -
- adrenergic blocking agents ⁇ -adrenergic agonists, parasypathomimetic agents.
- cholinesterase inhibitors carbonic anhydrase inhibitors, and prostaglandins; combinations of anti-glaucoma agents; antioxidants; nutritional supplements; drugs for the treatment of
- cystoid macular edema including, without limitation, non-steroidal anti-inflammatory agents; drugs for the treatment of ARMD, including, without limitation, angiogenesis
- angiostatic steroids for the treatment of diseases or conditions of the posterior segment of the eye, including, without limitation,
- ARMD CNV
- retinopathies retinitis, uveitis, macular edema, and glaucoma.
- Inner core 26 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent or the drug core.
- inner core 26 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods.
- the pharmaceutically active agent is preferably
- inner core 26 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage. If inner core 26 is a hydrogel, the hydrogel may
- the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active
- Device 10 may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and
- device 10 is formed using conventional injection molding
- Inner core 26 is preferably disposed in well 22 after the formation of body 12 of device 10.
- Retaining member 28 is preferably resilient enough to allow inner core 26 to be inserted through opening 24 and then to return to its position as shown in
- FIG. 1 Device 10 is preferably surgically placed proximate a target tissue. The surgeon first makes an incision proximate the target tissue. Next, the surgeon performs a blunt
- surgeon uses forceps to hold device 10 with internal surface 14 facing the target tissue and
- the surgeon may or may not use sutures to fix device 10 to the underlying tissue, depending on the specific tissue. After placement, the surgeon sutures the opening and places a strip of antibiotic ointment on the surgical wound.
- body 12 including the geometry of internal surface 14, well 22, opening 24, and retaining member 28, facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core
- Device 10 can be used to deliver a pharmaceutically effective amount of a
- physicochemical properties of the pharmaceutically active agent employed include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity. After inner core 26 no longer contains active agent, a surgeon may easily remove device 10. In addition, the "pre-formed" tunnel facilitates the
- FIGS. 3 through 6B schematically illustrate an ophthalmic drug delivery device 50
- Device 50 may be used in any case where localized delivery of a pharmaceutically active agent to the eye is required. Device 50 is particularly useful for localized delivery of active agents to the
- a preferred use for device 50 is the delivery of pharmaceutically active agents to the retina proximate the macula for treating ARMD, choroidial neovascularization (CNV), retinopathies, retinitis, uveitis, macular edema, and
- device 50 may also be utilized for localized delivery of
- Eye 52 has a cornea 54, a lens 56, a sclera 58, a choroid 60. a retina 62, and an optic nerve 64.
- An anterior segment 66 of eye 52 generally includes the portions of eye 52 anterior of a line
- a posterior segment 68 of eye 52 generally includes the portions of eye 52 posterior of line 67.
- Retina 62 is physically attached to choroid 60 in a circumferential manner proximate pars plana 70.
- Retina 62 has a macula 72 located slightly lateral to its optic
- macula 72 is comprised primarily of retinal cones and is the region of maximum visual acuity in retina 62.
- a Tenon's capsule or Tenon's membrane 74 is disposed on sclera 58.
- a conjunctiva 76 covers a short area of
- Conjunctiva 76 is disposed on top of Tenon's capsule 74.
- device 50 is preferably disposed directly on the outer surface of sclera 58, below Tenon's capsule 74 for treatment of most posterior segment diseases or conditions.
- device 50 is preferably disposed directly on the outer surface of
- FIGS. 5, 6 A, and 6B schematically illustrate drug delivery device 50 in greater
- Device 50 generally includes a body 80 having a scleral surface 82 and an orbital
- Scleral surface 82 is preferably designed with a radius of curvature that facilitates direct contact with sclera 58.
- Orbital surface 84 is preferably designed with a radius of curvature that facilitates implantation under Tenon's capsule 74.
- Body 80 is preferably designed with a radius of curvature that facilitates implantation under Tenon's capsule 74.
- body 80 may alternatively have a geometry similar to that of device 10a shown in FIG. 2. In addition, body 80 may have
- body 80 may have a generally cylindrical, oval, square, or other polygonal three-dimensional geometry.
- Body 80 includes a well or cavity 102 having an opening 104 to scleral surface 82.
- An inner core 106 is preferably disposed in well 102.
- Inner core 106 is preferably a tablet comprising one or more pharmaceutically active agents.
- inner core 106 may comprise a conventional hydrogel having one or more pharmaceutically active agents disposed therein.
- a retaining member 108 is preferably disposed proximate opening 104. Retaining member 108 prevents inner core 106 from falling out of well 102.
- retaining member 108 is preferably a continuous rim or lip disposed circumferentially around opening 104 having a diameter slightly less than the diameter of tablet 106.
- retaining member 108 may comprise one or more members that extend from body 80 into opening 104.
- inner core 106 may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents.
- a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents.
- scleral surface 82 is formed without opening 104, and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion of scleral surface 82
- device 50 may be formed without
- the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughout body 80 of device 50.
- the pharmaceutically active agent diffuses through body 80 into the target tissue.
- the geometry and dimensions of device 50 maximize communication between the pharmaceutically active agent of inner core 106 and the tissue underlying scleral surface 82.
- Scleral surface 82 preferably physically contacts the outer surface of sclera 58.
- inner core 106 may be formed so that surface 106a physically contacts the outer surface of sclera 58.
- scleral surface 82 may be disposed proximate the outer surface of sclera 58.
- device 50 may be disposed in the periocular tissues just above the outer surface of sclera 58 or intra- lamellarly within sclera 58.
- Body 80 preferably comprises a biocompatible, non-bioerodable material.
- Body 80 more preferably comprises a biocompatible, non-bioerodable polymeric composition.
- the polymeric composition comprising body 80, and the polymers suitable for use in the polymeric compositions of body 80 may be any of the compositions and polymers described hereinabove for body 12 of device 10.
- Body 80 most preferably is made from a polymeric composition comprising silicone.
- Body 80 is preferably impermeable to the pharmaceutically active agent of inner core 106.
- the diameter of well 102 may be slightly less than the
- body 80 may be formed without retaining member 108, if desired.
- Inner core 106 may comprise any ophthalmically acceptable pharmaceutically
- active agents suitable for localized delivery include the pharmaceutically active agents listed hereinabove for inner core 26 of device
- Inner core 106 may also comprise conventional non-active excipients to enhance the
- inner core 106 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods.
- the pharmaceutically active agent is preferably distributed evenly throughout the tablet.
- inner core 106 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage.
- inner core 106 is a hydrogel, the hydrogel may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active
- Device 50 may be made by conventional polymer processing methods, including,
- device 50 is formed using conventional injection molding techniques as described hereinabove for device 10.
- Device 50 is preferably surgically placed directly on the outer surface of sclera 58
- Tenon's capsule 74 using a simple surgical technique that is capable of being performed in an outpatient setting. The surgeon first performs a peritomy in one of the
- the surgeon performs the peritomy in the infra-temporal quadrant, about 3 mm posterior to limbus 77 of eye 52. Once this incision is made, the
- antero-posterior tunnel Once the tunnel is formed, the surgeon uses forceps to hold device 50 with scleral surface 82 facing sclera 58 and distal end 92 away from the surgeon. The surgeon then introduces device 50 into the tunnel in a generally circular
- the surgeon then closes the peritomy by suturing Tenon's capsule 74 and conjunctiva 76 to sclera 58. After closing, the surgeon places a strip of antibiotic ointment on the surgical wound. Alternatively, the surgeon may suture proximal end 90 of device 50 to sclera 58 to hold device 50 in the desired location before closure of the tunnel.
- the surgeon utilizes the above-described technique to position inner core 106 of device 50 in one of two preferred locations in the infra-temporal quadrant of eye 52.
- One preferred location is directly on the outer surface of sclera 58, below Tenon's capsule 74, with inner core 106 positioned proximate to, but not directly above, macula 72.
- a surgeon may position inner core 106 of device 50 at this location by moving distal end 92 of device 50 below the inferior oblique muscle in a direction generally parallel to the lateral rectus muscle.
- a second preferred location is
- the pharmaceutically active agent of inner core 106 is preferably one of the angiostatic steroids disclosed in U.S. Patent Nos. 5,679,666 and 5,770,592.
- body 80 of device 50 including the geometry of scleral surface 82, well 102, opening 104, and retaining member 108, facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from
- inner core 106 through sclera 58, choroid 60, and into retina 62.
- sclera 58 the absence of a polymer layer or membrane between inner core 106 and sclera 58 greatly enhances
- device 50 can be used to deliver a pharmaceutically effective
- a pharmaceutically active agent to retina 62 for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed.
- Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity.
- EXAMPLE A device 50 was surgically implanted on the outer surface of the sclera. Below the
- Retaining member 108 had a thickness 116 of about 0.15 mm.
- Scleral surface 82 had a radius of curvature of about 8.5 mm and an arc length of about 18 mm.
- Inner core 106 was a cylindrical tablet with a diameter of about 5.0 mm and a thickness of about 1.5 mm. Opening 104 had a diameter of about 3.8 mm. Well 102 had a diameter of about 4.4 mm.
- a 10 mm diameter circular zone of retinal tissue was harvested from a third site located between the second site and the target site. Similar 10 mm diameter circular zones of choroidal tissue were also harvested at the target site, second site, and third site. All these tissues were separately homogenized, and the concentration of angiostatic steroid in each of these tissues was determined via an ocular pharmacokinetic study using high performance liquid chromatography and mass
- FIG. 7 shows the mean concentration of 4,9(1 l)-Pregnadien-17 ⁇ ,21-diol-3,20- dione in the retina and the choroid at the target site as a function of time.
- device 50 delivered a pharmaceutically effective and generally constant amount of 4,9(11)-
- device 50 also delivered a localized dose of angiostatic steroid to the
- the present invention provides improved devices and methods for safe, effective, rate-controlled, localized delivery of a
- such devices are useful in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject.
- such devices are especially useful for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD,
- CNV CNV
- retinopathies CNV
- retinitis CNV
- retinitis CNV
- retinitis CNV
- retinitis CNV
- retinitis CNV
- retinitis CNV
- retinitis CNV
- retinitis CNV
- retinitis CNV
- retinitis CNV
- retinitis CNV
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002383499A CA2383499C (en) | 1999-10-21 | 2000-09-12 | Drug delivery device |
DE60016271T DE60016271T2 (en) | 1999-10-21 | 2000-09-12 | drug delivery |
MXPA02002338A MXPA02002338A (en) | 1999-10-21 | 2000-09-12 | Drug delivery device. |
AT00961836T ATE283013T1 (en) | 1999-10-21 | 2000-09-12 | MEDICATION DELIVERY DEVICE |
AU73733/00A AU768400B2 (en) | 1999-10-21 | 2000-09-12 | Drug delivery device |
DK00961836T DK1221917T3 (en) | 2000-09-12 | 2000-09-12 | Drug delivery device |
PL355263A PL196988B1 (en) | 1999-10-21 | 2000-09-12 | Drug delivery device |
EP00961836A EP1221917B1 (en) | 1999-10-21 | 2000-09-12 | Drug delivery device |
BRPI0014929-2A BR0014929B1 (en) | 1999-10-21 | 2000-09-12 | device for dispensing ophthalmic medicament. |
JP2001531069A JP4837861B2 (en) | 1999-10-21 | 2000-09-12 | Drug delivery formulation |
DK04018677T DK1473003T3 (en) | 1999-10-21 | 2000-09-12 | Drug delivery device |
HK02108313.1A HK1048427B (en) | 1999-10-21 | 2002-11-15 | Drug delivery device |
AU2004200908A AU2004200908B2 (en) | 1999-10-21 | 2004-03-02 | Drug delivery device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16067399P | 1999-10-21 | 1999-10-21 | |
US60/160,673 | 1999-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001028472A1 true WO2001028472A1 (en) | 2001-04-26 |
Family
ID=22577913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/024983 WO2001028472A1 (en) | 1999-10-21 | 2000-09-12 | Drug delivery device |
Country Status (22)
Country | Link |
---|---|
US (3) | US6413540B1 (en) |
EP (2) | EP1473003B1 (en) |
JP (1) | JP4837861B2 (en) |
KR (1) | KR100732262B1 (en) |
CN (1) | CN1292721C (en) |
AR (3) | AR026165A1 (en) |
AT (2) | ATE283013T1 (en) |
AU (2) | AU768400B2 (en) |
BR (1) | BR0014929B1 (en) |
CA (1) | CA2383499C (en) |
CY (1) | CY1109489T1 (en) |
DE (2) | DE60040876D1 (en) |
DK (1) | DK1473003T3 (en) |
ES (2) | ES2231257T3 (en) |
HK (2) | HK1048427B (en) |
MX (1) | MXPA02002338A (en) |
PL (1) | PL196988B1 (en) |
PT (2) | PT1221917E (en) |
TR (1) | TR200201047T2 (en) |
TW (1) | TW555575B (en) |
WO (1) | WO2001028472A1 (en) |
ZA (2) | ZA200201188B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002089767A1 (en) * | 2001-05-03 | 2002-11-14 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
EP1420716A1 (en) * | 2001-08-29 | 2004-05-26 | Ricardo A. P. De Carvalho | An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues |
CN100349562C (en) * | 2001-07-23 | 2007-11-21 | 爱尔康公司 | Ophthalmic drug delivery device |
US7749528B2 (en) | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
US10449145B2 (en) | 2013-05-02 | 2019-10-22 | Retina Foundation Of The Southwest | Two-layer ocular implant |
Families Citing this family (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ509797A (en) * | 1998-07-10 | 2003-11-28 | Univ Sydney | Prophylactic treatments of neovascularisation in macular degeneration using a steroid |
MXPA01010832A (en) | 1999-04-26 | 2003-06-30 | Gmp Vision Solutions Inc | Shunt device and method for treating glaucoma. |
US7943162B2 (en) | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
DE60040876D1 (en) * | 1999-10-21 | 2009-01-02 | Alcon Inc | medication supply |
US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
US20050119737A1 (en) * | 2000-01-12 | 2005-06-02 | Bene Eric A. | Ocular implant and methods for making and using same |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
AR030345A1 (en) * | 2000-08-14 | 2003-08-20 | Alcon Inc | METHOD OF TREATMENT OF DISORDERS RELATED TO ANGIOGENESIS |
US6756049B2 (en) * | 2000-12-29 | 2004-06-29 | Bausch & Lomb Incorporated | Sustained release drug delivery devices |
JP2004521882A (en) * | 2001-01-03 | 2004-07-22 | ボシュ・アンド・ロム・インコーポレイテッド | Sustained release drug delivery device with assembled permeable plug |
CA2432203C (en) | 2001-01-03 | 2008-03-25 | Michael J. Brubaker | Sustained release drug delivery devices with multiple agents |
JP2004520900A (en) * | 2001-01-26 | 2004-07-15 | ボシュ・アンド・ロム・インコーポレイテッド | Improved manufacturing method of sustained release drug delivery device |
EP1977724A1 (en) | 2001-04-07 | 2008-10-08 | Glaukos Corporation | System for treating ocular disorders |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US7488303B1 (en) * | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
US7094225B2 (en) | 2001-05-03 | 2006-08-22 | Glaukos Corporation | Medical device and methods of use of glaucoma treatment |
ATE506929T1 (en) | 2001-06-12 | 2011-05-15 | Univ Johns Hopkins Med | RESERVOIR DEVICE FOR INTRAOCULAR MEDICINAL DELIVERY |
PT1409065E (en) * | 2001-07-23 | 2007-03-30 | Alcon Inc | Ophthalmic drug delivery device |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US20060034929A1 (en) * | 2001-12-27 | 2006-02-16 | Brubaker Michael J | Sustained release drug delivery devices with prefabricated permeable plugs |
US7186232B1 (en) | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
WO2003105668A2 (en) * | 2002-06-01 | 2003-12-24 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Injection devices and methods for testing implants and for unimpeded target location testing |
US20070265582A1 (en) * | 2002-06-12 | 2007-11-15 | University Of Southern California | Injection Devices for Unimpeded Target Location Testing |
PL375024A1 (en) * | 2002-08-05 | 2005-11-14 | Alcon, Inc. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
DE10238310A1 (en) * | 2002-08-21 | 2004-03-04 | Erich Jaeger Gmbh | electrode assembly |
CA2498489C (en) * | 2002-09-29 | 2010-02-23 | Surmodics, Inc. | Method for subretinal administration of therapeutics including steroids;method for localizing pharmacodynamic action at the choroid and the retina; and related methods for treatment and/or prevention of retinal diseases |
WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
ZA200505989B (en) * | 2003-02-20 | 2006-12-27 | Alcon Inc | Use the steroids to treat ocular disorders |
EP1594511A2 (en) * | 2003-02-20 | 2005-11-16 | Alcon, Inc. | Formulations of glucocorticoids to treat pathologic ocular angiogenesis |
US20050261668A1 (en) * | 2003-03-28 | 2005-11-24 | Bausch & Lomb Incorporated | Drug delivery device |
US20040236343A1 (en) * | 2003-05-23 | 2004-11-25 | Taylor Jon B. | Insertion tool for ocular implant and method for using same |
KR20060019579A (en) * | 2003-06-13 | 2006-03-03 | 알콘, 인코퍼레이티드 | Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis |
AU2004249256A1 (en) * | 2003-06-20 | 2004-12-29 | Alcon, Inc. | Treatment of AMD with combination of ingredients |
US20040265356A1 (en) * | 2003-06-30 | 2004-12-30 | Bausch & Lomb Incorporated | Drug delivery device |
JP2007526019A (en) * | 2003-07-10 | 2007-09-13 | アルコン,インコーポレイティド | Ophthalmic drug delivery device |
US8167855B2 (en) | 2003-08-26 | 2012-05-01 | Vista Scientific Llc | Ocular drug delivery device |
EP3168304A1 (en) * | 2003-08-27 | 2017-05-17 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
CN102144961A (en) * | 2003-09-18 | 2011-08-10 | 参天制药株式会社 | Transscleral delivery |
US20050158365A1 (en) * | 2003-12-22 | 2005-07-21 | David Watson | Drug delivery device with mechanical locking mechanism |
US20050136095A1 (en) * | 2003-12-22 | 2005-06-23 | Brian Levy | Drug delivery device with suture ring |
US7276050B2 (en) * | 2004-03-02 | 2007-10-02 | Alan Franklin | Trans-scleral drug delivery method and apparatus |
US9549895B2 (en) * | 2004-04-23 | 2017-01-24 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US20060024350A1 (en) * | 2004-06-24 | 2006-02-02 | Varner Signe E | Biodegradable ocular devices, methods and systems |
US20060110428A1 (en) | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
US20060067980A1 (en) * | 2004-09-30 | 2006-03-30 | Bausch & Lomb Incorporated | Capsule for encasing tablets for surgical insertion into the human body |
US20060134162A1 (en) * | 2004-12-16 | 2006-06-22 | Larson Christopher W | Methods for fabricating a drug delivery device |
US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
WO2006086750A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
CN101180086A (en) * | 2005-04-08 | 2008-05-14 | 苏尔莫迪克斯公司 | Sustained release implants for subretinal delivery |
PL1919290T3 (en) * | 2005-07-12 | 2014-06-30 | Ampio Pharmaceuticals Inc | Methods and products for treatment of diseases |
US20070100199A1 (en) * | 2005-11-03 | 2007-05-03 | Lilip Lau | Apparatus and method of delivering biomaterial to the heart |
US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
US20070134244A1 (en) * | 2005-10-14 | 2007-06-14 | Alcon, Inc. | Combination treatment for pathologic ocular angiogenesis |
JP5528708B2 (en) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | Stable formulations and methods for preparing and using them |
US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
DK2010096T3 (en) * | 2006-03-31 | 2017-10-02 | Mati Therapeutics Inc | NASOLACRIMAL DRAINAGE SYSTEM IMPLANTS FOR PHARMACEUTICAL THERAPY |
US20070293807A1 (en) * | 2006-05-01 | 2007-12-20 | Lynch Mary G | Dual drainage pathway shunt device and method for treating glaucoma |
EP2019646A4 (en) * | 2006-05-04 | 2013-12-04 | Herbert Kaufman | Method, device, and system for delivery of therapeutic agents to the eye |
US7981096B2 (en) * | 2006-05-12 | 2011-07-19 | David Castillejos | Optic nerve head implant and medication delivery system |
CN101505696B (en) * | 2006-06-21 | 2012-11-14 | 庄臣及庄臣视力保护公司 | Punctal plugs for the delivery of active agents |
EP2043572B1 (en) | 2006-06-30 | 2014-12-31 | Aquesys Inc. | Apparatus for relieving pressure in an organ |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
US8721702B2 (en) | 2010-11-15 | 2014-05-13 | Aquesys, Inc. | Intraocular shunt deployment devices |
US10085884B2 (en) | 2006-06-30 | 2018-10-02 | Aquesys, Inc. | Intraocular devices |
US20120123316A1 (en) | 2010-11-15 | 2012-05-17 | Aquesys, Inc. | Intraocular shunts for placement in the intra-tenon's space |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
US8308701B2 (en) | 2010-11-15 | 2012-11-13 | Aquesys, Inc. | Methods for deploying intraocular shunts |
CA2668954C (en) | 2006-11-10 | 2020-09-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US20100034808A1 (en) * | 2006-11-21 | 2010-02-11 | Toru Nakazawa | Compositions and methods for preserving cells of the eye |
WO2008073576A1 (en) * | 2006-12-08 | 2008-06-19 | Alcon, Inc. | Drug delivery device |
CN103622778A (en) * | 2006-12-18 | 2014-03-12 | 爱尔康研究有限公司 | Devices and methods for ophthalmic drug delivery |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
BRPI0917135A2 (en) * | 2008-08-09 | 2015-11-10 | Massachusetts Inst Technology | medical device for extension and retention in a patient's seminal vesicle, ejaculatory duct, prostate or vas deferens, use of a resorbable elastomer, and osmotic pump device. |
US20100104654A1 (en) * | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
CA2757037C (en) | 2009-01-29 | 2019-08-06 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
JP5695035B2 (en) | 2009-06-03 | 2015-04-01 | フォーサイト・ビジョン5・インコーポレイテッドForsight Vision5,Inc. | Anterior eye drug supply |
SG176939A1 (en) * | 2009-06-22 | 2012-01-30 | Dmi Acquisition Corp | Method for treatment of diseases |
WO2010151531A1 (en) * | 2009-06-22 | 2010-12-29 | Dmi Acquistion Corp. | Methods and products for treatment of diseases |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
WO2011127064A2 (en) * | 2010-04-06 | 2011-10-13 | Allergan, Inc. | Sustained-release reservoir implants for intracameral drug delivery |
AU2011242465B2 (en) | 2010-04-23 | 2017-01-19 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
WO2011146483A1 (en) | 2010-05-17 | 2011-11-24 | Aerie Pharmaceuticals, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
AU2011285548B2 (en) | 2010-08-05 | 2014-02-06 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
RS61601B1 (en) | 2010-08-05 | 2021-04-29 | Forsight Vision4 Inc | Injector apparatus for drug delivery |
RS62540B1 (en) | 2010-08-05 | 2021-12-31 | Forsight Vision4 Inc | Apparatus to treat an eye |
US20120109054A1 (en) * | 2010-10-29 | 2012-05-03 | Vista Scientific Llc | Devices with an erodible surface for delivering at least one active agent to tissue over a prolonged period of time |
WO2012061045A2 (en) | 2010-11-01 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving retinal ganglion cells |
US20160256317A1 (en) | 2010-11-15 | 2016-09-08 | Aquesys, Inc. | Methods for implanting intraocular shunts |
AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
WO2012106714A1 (en) * | 2011-02-04 | 2012-08-09 | Taris Biomedical, Inc. | Implantable device for controlled release of low solubility drug |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
WO2013003467A2 (en) | 2011-06-27 | 2013-01-03 | Massachusetts Eye And Ear Infirmary | Methods for treating ocular inflammatory disorders |
EP2726016B1 (en) | 2011-06-28 | 2023-07-19 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
WO2013025840A1 (en) | 2011-08-15 | 2013-02-21 | Massachusetts Eye And Ear Infirmary | Methods for preserving photoreceptor cell viability following retinal detachment |
US9102105B2 (en) | 2011-09-13 | 2015-08-11 | Vista Scientific Llc | Method for forming an ocular drug delivery device |
EP3659495B1 (en) | 2011-09-13 | 2022-12-14 | Dose Medical Corporation | Intraocular physiological sensor |
WO2013040426A2 (en) | 2011-09-14 | 2013-03-21 | Forsight Labs, Llc | Ocular insert apparatus and methods |
WO2013040247A2 (en) | 2011-09-16 | 2013-03-21 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
CA2888805C (en) | 2011-10-21 | 2020-07-14 | Massachusetts Eye And Ear Infirmary | Methods and compositions for promoting axon regeneration and nerve function |
US9610195B2 (en) | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US10080682B2 (en) | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
US9808373B2 (en) | 2013-06-28 | 2017-11-07 | Aquesys, Inc. | Intraocular shunt implantation |
US8852136B2 (en) * | 2011-12-08 | 2014-10-07 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
EP2708209A1 (en) * | 2012-09-13 | 2014-03-19 | AJL Ophthalmic, S.A. | Scleral epimacular implant |
WO2014066775A1 (en) | 2012-10-26 | 2014-05-01 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
EP2914225B1 (en) * | 2012-11-01 | 2021-02-17 | Poway Retinal Technologies LLC | Retinal repair device |
AU2013361338A1 (en) | 2012-12-19 | 2015-08-06 | Ampio Pharmaceuticals, Inc. | Method for treatment of diseases |
PT2956476T (en) | 2013-02-18 | 2020-02-21 | Vegenics Pty Ltd | Ligand binding molecules and uses thereof |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
TW201507749A (en) | 2013-03-11 | 2015-03-01 | Sanofi Aventis Deutschland | Assembly for a drug delivery device |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
CA2905496A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
AU2014241163B2 (en) | 2013-03-28 | 2018-09-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
MX2016000364A (en) | 2013-07-12 | 2016-05-09 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions. |
AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
US9585790B2 (en) | 2013-11-14 | 2017-03-07 | Aquesys, Inc. | Intraocular shunt inserter |
US10143703B2 (en) | 2014-01-02 | 2018-12-04 | Massachusetts Eye And Ear Infirmary | Treating ocular neovascularization |
WO2015134812A1 (en) | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
DK3116997T3 (en) | 2014-03-10 | 2019-08-19 | Editas Medicine Inc | CRISPR / CAS-RELATED PROCEDURES AND COMPOSITIONS TO TREAT LEVER'S CONGENITAL AMAUROSIS 10 (LCA10) |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
WO2015148863A2 (en) | 2014-03-26 | 2015-10-01 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
WO2016011191A1 (en) | 2014-07-15 | 2016-01-21 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
SG11201700943TA (en) | 2014-08-08 | 2017-03-30 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
CA2967330A1 (en) | 2014-11-10 | 2016-05-19 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
KR102535217B1 (en) | 2015-04-24 | 2023-05-19 | 에디타스 메디신, 인코포레이티드 | Assessment of CAS9 Molecule/Guide RNA Molecule Complexes |
WO2016187426A1 (en) | 2015-05-19 | 2016-11-24 | Amorphex Therapeutics Llc | A device that delivers a sustained low-dose of a myopia-suppressing drug |
BR112017025859A2 (en) | 2015-06-03 | 2018-08-14 | Aquesys, Inc. | external ab intraocular shunt placement |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
JP7408284B2 (en) | 2015-10-30 | 2024-01-05 | エディタス・メディシン、インコーポレイテッド | CRISPR/CAS-related methods and compositions for treating herpes simplex virus |
CN113069681B (en) | 2015-11-20 | 2022-12-23 | 弗赛特影像4股份有限公司 | Method of manufacturing a therapeutic device for sustained drug delivery |
US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
ES2837524T3 (en) | 2016-04-05 | 2021-06-30 | Forsight Vision4 Inc | Implantable ocular drug delivery devices |
WO2017184881A1 (en) | 2016-04-20 | 2017-10-26 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
WO2017210627A1 (en) | 2016-06-02 | 2017-12-07 | Aquesys, Inc. | Intraocular drug delivery |
AU2017305404B2 (en) | 2016-08-02 | 2023-11-30 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
US11040019B2 (en) | 2016-08-19 | 2021-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration |
EP3532616A1 (en) | 2016-10-28 | 2019-09-04 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus |
CN110545836A (en) | 2017-01-24 | 2019-12-06 | 马克雷根有限公司 | Treatment of age-related macular degeneration and other ocular diseases with apolipoprotein mimics |
EP3570888A1 (en) | 2017-03-03 | 2019-11-27 | MacRegen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
WO2018170184A1 (en) | 2017-03-14 | 2018-09-20 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
EP3618841B1 (en) | 2017-05-05 | 2023-03-22 | University of Pittsburgh - of The Commonwealth System of Higher Education | Ocular applications of matrix bound vesicles (mbvs) |
US10905770B2 (en) | 2017-07-17 | 2021-02-02 | Macregen, Inc. | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
CN111655206B (en) | 2017-11-21 | 2022-10-14 | 弗赛特影像4股份有限公司 | Fluid exchange device for expandable port delivery system and method of use |
EP3758736A1 (en) | 2018-03-02 | 2021-01-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Use of il-34 to treat retinal inflammation and neurodegeneration |
US10952898B2 (en) | 2018-03-09 | 2021-03-23 | Aquesys, Inc. | Intraocular shunt inserter |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
KR20210133993A (en) | 2019-02-25 | 2021-11-08 | 에디타스 메디신, 인코포레이티드 | CRISPR/RNA-guided nuclease-related methods and compositions for treating RHO-associated autosomal-dominant retinitis pigmentosa (ADRP) |
AU2021208631A1 (en) | 2020-01-17 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene therapy for treatment of CRX-autosomal dominant retinopathies |
AU2021300425A1 (en) | 2020-07-02 | 2023-02-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cyclic compounds for use in treating retinal degeneration |
EP4323522A1 (en) | 2021-04-16 | 2024-02-21 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
CN115737892A (en) * | 2022-11-21 | 2023-03-07 | 诺莱生物医学科技有限公司 | Elastic dressing carrying repair matrix and preparation method thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4022553A1 (en) * | 1990-07-16 | 1992-01-23 | Hund Helmut Gmbh | Medical contact lens - with recess contg. therapeutically or diagnostically active substance |
US5403901A (en) | 1990-11-07 | 1995-04-04 | Nestle S.A. | Flexible, high refractive index polymers |
US5476511A (en) | 1992-05-04 | 1995-12-19 | Allergan, Inc. | Subconjunctival implants for ocular drug delivery |
WO1997014415A1 (en) * | 1995-10-19 | 1997-04-24 | F.H. Faulding & Co. Limited | Analgesic immediate and controlled release pharmaceutical composition |
US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
WO1998023228A1 (en) * | 1996-11-25 | 1998-06-04 | Alza Corporation | Directional drug delivery stent |
US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
WO1998043611A1 (en) * | 1997-03-31 | 1998-10-08 | Alza Corporation | Diffusional implantable delivery system |
US5824072A (en) | 1993-11-15 | 1998-10-20 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5824073A (en) | 1996-03-18 | 1998-10-20 | Peyman; Gholam A. | Macular indentor for use in the treatment of subretinal neovascular membranes |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3416530A (en) | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
US3828777A (en) | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
US4014725A (en) * | 1975-03-27 | 1977-03-29 | Union Carbide Corporation | Method of making carbon cloth from pitch based fiber |
US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
US4300557A (en) | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US5147647A (en) | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
US5322691A (en) | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US4759746A (en) * | 1987-05-14 | 1988-07-26 | Straus Jeffrey G | Retro-bulbar needle |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
DE3905050A1 (en) | 1989-02-18 | 1990-08-30 | Lohmann Therapie Syst Lts | THERAPEUTIC SYSTEM FOR DELAYED AND CONTROLLED TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE SUBSTANCES (II) |
US4946450A (en) | 1989-04-18 | 1990-08-07 | Biosource Genetics Corporation | Glucan/collagen therapeutic eye shields |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
FR2690846B1 (en) | 1992-05-05 | 1995-07-07 | Aiache Jean Marc | GALENIC FORM FOR EYE ADMINISTRATION AND METHOD OF PREPARATION. |
WO1994005257A1 (en) | 1992-09-08 | 1994-03-17 | Allergan, Inc. | Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
AU704591B2 (en) | 1994-04-04 | 1999-04-29 | William R. Freeman | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
US5710165A (en) | 1994-07-06 | 1998-01-20 | Synthelabo | Use of polyamine antagonists for the treatment of glaucoma |
CN2219115Y (en) * | 1994-08-31 | 1996-02-07 | 程康 | Pulse medicine therapeutic apparatus for myopia |
AUPM897594A0 (en) | 1994-10-25 | 1994-11-17 | Daratech Pty Ltd | Controlled release container |
DE69529572T2 (en) | 1994-11-10 | 2003-06-18 | Univ Kentucky Res Foundation L | IMPLANTABLE REFILLABLE DEVICE WITH CONTROLLED RELEASE FOR ADMINISTERING MEDICINAL SUBSTANCES DIRECTLY ON AN INNER PART OF THE BODY |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
CN1124164C (en) | 1995-05-14 | 2003-10-15 | 奥普通诺尔有限公司 | Intraocular implant, delivery device, and method of implantation |
EP1057486A1 (en) * | 1995-11-17 | 2000-12-06 | Alcon Laboratories, Inc. | Use of drug combination for treating Glaucoma |
US5743274A (en) | 1996-03-18 | 1998-04-28 | Peyman; Gholam A. | Macular bandage for use in the treatment of subretinal neovascular members |
US5904144A (en) | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
JP3309175B2 (en) | 1996-03-25 | 2002-07-29 | 参天製薬株式会社 | Scleral plug containing proteinaceous drug |
US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US6120460A (en) * | 1996-09-04 | 2000-09-19 | Abreu; Marcio Marc | Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions |
JP2001513369A (en) | 1997-08-11 | 2001-09-04 | アラーガン・セイルズ・インコーポレイテッド | Sterile bioerodible implant devices and methods with improved biocompatibility |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6066671A (en) | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
ATE365550T1 (en) | 1998-03-13 | 2007-07-15 | Univ Johns Hopkins Med | USE OF A PROTEIN KINASE INHIBITOR SUCH AS GENISTEIN IN THE TREATMENT OF DIABETIC RETINOPATHY |
DE19847192A1 (en) | 1998-10-13 | 2000-04-27 | Wella Ag | Colorant for fibers, especially human hair, contains 4-nitrophenyl-N-heterocyclic, -cycloalkane, -alkoxyalkane or -amine compound |
US6146366A (en) | 1998-11-03 | 2000-11-14 | Ras Holding Corp | Device for the treatment of macular degeneration and other eye disorders |
US6399655B1 (en) | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
DE60040876D1 (en) * | 1999-10-21 | 2009-01-02 | Alcon Inc | medication supply |
-
2000
- 2000-09-12 DE DE60040876T patent/DE60040876D1/en not_active Expired - Lifetime
- 2000-09-12 TR TR2002/01047T patent/TR200201047T2/en unknown
- 2000-09-12 PT PT00961836T patent/PT1221917E/en unknown
- 2000-09-12 EP EP04018677A patent/EP1473003B1/en not_active Expired - Lifetime
- 2000-09-12 MX MXPA02002338A patent/MXPA02002338A/en active IP Right Grant
- 2000-09-12 DK DK04018677T patent/DK1473003T3/en active
- 2000-09-12 DE DE60016271T patent/DE60016271T2/en not_active Expired - Lifetime
- 2000-09-12 PT PT04018677T patent/PT1473003E/en unknown
- 2000-09-12 BR BRPI0014929-2A patent/BR0014929B1/en not_active IP Right Cessation
- 2000-09-12 PL PL355263A patent/PL196988B1/en not_active IP Right Cessation
- 2000-09-12 WO PCT/US2000/024983 patent/WO2001028472A1/en active IP Right Grant
- 2000-09-12 ES ES00961836T patent/ES2231257T3/en not_active Expired - Lifetime
- 2000-09-12 AT AT00961836T patent/ATE283013T1/en active
- 2000-09-12 EP EP00961836A patent/EP1221917B1/en not_active Expired - Lifetime
- 2000-09-12 JP JP2001531069A patent/JP4837861B2/en not_active Expired - Fee Related
- 2000-09-12 CA CA002383499A patent/CA2383499C/en not_active Expired - Fee Related
- 2000-09-12 AU AU73733/00A patent/AU768400B2/en not_active Ceased
- 2000-09-12 US US09/660,000 patent/US6413540B1/en not_active Expired - Lifetime
- 2000-09-12 ES ES04018677T patent/ES2315598T3/en not_active Expired - Lifetime
- 2000-09-12 AT AT04018677T patent/ATE414494T1/en active
- 2000-09-12 KR KR1020027005020A patent/KR100732262B1/en not_active IP Right Cessation
- 2000-09-12 CN CNB008131864A patent/CN1292721C/en not_active Expired - Fee Related
- 2000-10-03 AR ARP000105210A patent/AR026165A1/en active IP Right Grant
- 2000-10-05 TW TW089120788A patent/TW555575B/en not_active IP Right Cessation
-
2002
- 2002-02-12 ZA ZA200201188A patent/ZA200201188B/en unknown
- 2002-02-12 ZA ZA200201189A patent/ZA200201189B/en unknown
- 2002-07-01 US US10/186,960 patent/US6808719B2/en not_active Expired - Lifetime
- 2002-11-15 HK HK02108313.1A patent/HK1048427B/en not_active IP Right Cessation
-
2003
- 2003-03-25 AR ARP030101035A patent/AR039132A2/en unknown
- 2003-03-25 AR ARP030101034A patent/AR039131A2/en unknown
-
2004
- 2004-03-02 AU AU2004200908A patent/AU2004200908B2/en not_active Ceased
- 2004-10-04 US US10/957,910 patent/US20050112175A1/en not_active Abandoned
-
2005
- 2005-03-08 HK HK05102024.1A patent/HK1072177A1/en not_active IP Right Cessation
-
2009
- 2009-01-22 CY CY20091100083T patent/CY1109489T1/en unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4022553A1 (en) * | 1990-07-16 | 1992-01-23 | Hund Helmut Gmbh | Medical contact lens - with recess contg. therapeutically or diagnostically active substance |
US5403901A (en) | 1990-11-07 | 1995-04-04 | Nestle S.A. | Flexible, high refractive index polymers |
US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5476511A (en) | 1992-05-04 | 1995-12-19 | Allergan, Inc. | Subconjunctival implants for ocular drug delivery |
US5824072A (en) | 1993-11-15 | 1998-10-20 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
WO1997014415A1 (en) * | 1995-10-19 | 1997-04-24 | F.H. Faulding & Co. Limited | Analgesic immediate and controlled release pharmaceutical composition |
US5824073A (en) | 1996-03-18 | 1998-10-20 | Peyman; Gholam A. | Macular indentor for use in the treatment of subretinal neovascular membranes |
WO1998023228A1 (en) * | 1996-11-25 | 1998-06-04 | Alza Corporation | Directional drug delivery stent |
WO1998043611A1 (en) * | 1997-03-31 | 1998-10-08 | Alza Corporation | Diffusional implantable delivery system |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002089767A1 (en) * | 2001-05-03 | 2002-11-14 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
CN100349562C (en) * | 2001-07-23 | 2007-11-21 | 爱尔康公司 | Ophthalmic drug delivery device |
EP1420716A1 (en) * | 2001-08-29 | 2004-05-26 | Ricardo A. P. De Carvalho | An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues |
US7749528B2 (en) | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
EP1420716A4 (en) * | 2001-08-29 | 2010-10-27 | Carvalho Ricardo A P De | An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues |
EP1420716B1 (en) * | 2001-08-29 | 2012-08-15 | Ricardo A. P. De Carvalho | An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues |
US10449145B2 (en) | 2013-05-02 | 2019-10-22 | Retina Foundation Of The Southwest | Two-layer ocular implant |
US10881609B2 (en) | 2013-05-02 | 2021-01-05 | Retina Foundation Of The Southwest | Methods for treating eye disorders using ocular implants |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6413540B1 (en) | Drug delivery device | |
US7943162B2 (en) | Drug delivery device | |
US6986900B2 (en) | Ophthalmic drug delivery device | |
EP1221919B1 (en) | Ophthalmic drug delivery device | |
US7094226B2 (en) | Ophthalmic drug delivery device | |
AU2002319606A1 (en) | Ophthalmic drug delivery device | |
AU2002319596A1 (en) | Ophthalmic drug delivery device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP KR MX PL TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002/01188 Country of ref document: ZA Ref document number: 200201188 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000961836 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 73733/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2383499 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/002338 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008131864 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2001 531069 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/01047 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027005020 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027005020 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000961836 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 73733/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000961836 Country of ref document: EP |